Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Misses Expectations By $0.15 EPS

Travere Therapeutics (NASDAQ:TVTX) posted its earnings results on Thursday. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15), Zacks reports. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%.

Travere Therapeutics Price Performance

TVTX opened at $23.58 on Friday. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $25.29. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The business has a fifty day moving average price of $19.58 and a 200 day moving average price of $16.48.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. The trade was a 49.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Peter Heerma sold 1,584 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total value of $30,000.96. Following the transaction, the insider now directly owns 106,374 shares of the company’s stock, valued at $2,014,723.56. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock valued at $4,674,259 in the last three months. 3.75% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on TVTX. Canaccord Genuity Group raised their price objective on Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. HC Wainwright raised their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, January 15th. Barclays raised their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Evercore ISI raised their price objective on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Finally, Scotiabank raised their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.